SciBase Secures SEK 57.5M in Rights Issue, Eyes US Melanoma Market Expansion

  • SciBase raised SEK 57.5M through a rights issue, with 73.4% subscribed by shareholders and the remainder guaranteed by Bergs Securities.
  • The issue included 3.8M new shares, diluting existing shares by ~27%.
  • Proceeds will fund US commercialization, particularly in melanoma diagnostics.
  • CEO Pia Renaudin highlights upcoming reimbursement milestones in the US.
  • Board Chairman Jesper Høiland notes strong shareholder support ahead of CEO transition.

SciBase's successful rights issue underscores investor confidence in its AI-driven dermatology diagnostics platform, particularly as it targets the lucrative US melanoma market. The capital raise comes at a critical juncture, with reimbursement milestones looming and a leadership transition on the horizon. The company's ability to execute on its US strategy will be a key determinant of its long-term growth trajectory in a sector increasingly dominated by AI-driven diagnostic tools.

US Market Penetration
How SciBase's focus on melanoma diagnostics will impact its position in the competitive US healthcare market.
Reimbursement Milestones
Whether the upcoming reimbursement decisions will accelerate adoption of Nevisense in key markets.
Leadership Transition
The pace at which the new CEO can sustain momentum in commercialization efforts.